HINDVyome Holdings Inc.
HIND
Vyome Holdings Inc.35,060
Mkt Cap
$15.51MVolume
21,484.0052W High
$56.3852W Low
$1.75PE Ratio
0.03HIND Fundamentals
Price
$2.21Prev Close
$2.22Open
$2.2650D MA
$2.51Beta
0.18Avg. Volume
41,227.58EPS (Annual)
-$4.75P/B
5.36Rev/Employee
$17,761.89$3.80
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety...
Business Wire·13d ago
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Holdings, Inc., (Vyome) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq. This quarter marks Vyomes first annual...
Business Wire·24d ago
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Livechain, Inc. (Livechain) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading...
Business Wire·2mo ago
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed...
Business Wire·2mo ago
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it...
Business Wire·2mo ago
Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key...
Business Wire·3mo ago
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced its subsidiary, LiveChain, Inc. (Livechain or LICH) (OTC Markets: LICH) has executed a binding letter of intent (LOI) with Remus Capital, a...
Business Wire·4mo ago
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds...
Business Wire·4mo ago
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings, Inc., (Vyome) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the USIndia innovation corridor, today announced its financial results and a series of...
Business Wire·5mo ago
Vyome Holdings Announces Results of Annual Shareholder Meeting
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election Krishna K. Gupta, Shiladitya Sengupta, and...
Business Wire·6mo ago
<
1
2
...
>